Rahman 9-marker MALDI MS panel for Lung Cancer
This panel was derived from the proteomic analysis of bronchial lesions that could predict the diagnosis of lung cancer. Nine matrix-assisted laser desorption ionization mass spectrometry (MALDI MS) mass to charge ratio features were selected to build a prediction model diagnostic of lung cancer. One signature was not able to be associated with a particular protein. The remaining eight signatures are derived from: Thymosin beta-4 (TMSB4X), Macrophage migration inhibitory factor (MIF), Des-ubiquitin (Ubiquitin-Gly-Gly), Ubiquitin, Acyl-coA binding protein (ACBP, also known as DBI), Cystatin A (CSTA), and Cytochrome c.
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
Determining the probability of having lung cancer based on a novel proteomic signature of bronchial lesions may have important clinical implications. This signature may facilitate the diagnosis of lung cancer and the monitoring of high-risk individuals for lung cancer in surveillance and chemoprevention trials.
No associated resources found.